The Quintuple Aim: A New Direction for Healthcare Improvement

By Michael Awood

October 26, 2023

Illustration of the Quintuple Aim framework in healthcare, highlighting the five aims: improving population health, enhancing care experience, cost efficiency, provider wellbeing, and health equity.

The healthcare industry has faced significant challenges recently which has led to escalating costs. These have also continued to expand the disparities within healthcare worldwide. The COVID-19 pandemic brought these to light, with the marginalised communities experiencing higher rates of infection, morbidity, and mortality. These communities also continued to experience greater care disruptions. But what can be done about this? How could technology look to improve the outcomes and provide value? The quintuple framework proposes valuable aspects to improve healthcare systems and coupled with this, AI technologies can look to scale these improvements.

 

The Quintuple Aim

The need to optimise healthcare outcomes and reduce economic waste is more critical than ever. The triple aim was introduced as a beacon to guide healthcare improvements, focusing on enhancing population health, improving care experience, and promoting cost efficiency. However, the rising burnout rates among physicians and the increasing desire to leave the industry necessitated the inclusion of a fourth aim: addressing provider well-being. Without this, quality improvements would be unsustainable. The fifth aim was updated to include health equity, which ensures that we explicitly address equity and actively explore new efforts to promote it.

The quintuple aims for healthcare improvement are:

  1. Improving population health
  2. Enhancing care experience
  3. Cost Efficiency
  4. Provider Wellbeing
  5. Health Equity

 

The Role of Technology and Policy

Technology, particularly AI, plays a crucial role in achieving these aims. AI can improve access to equitable health, ensure cost-effectiveness through predictive algorithms, and manage procedural or administrative work through virtual assistants. Oracle Health has recently shown its new work in the healthcare space and optimising clinical models through the use of LMMs (multimodal models), by launching their digital assistant. The view is that it reduces the cognitive load on clinicians optimising the clinical delivery process, which ultimately also keeps it human. In turn, improvements to patient safety (increased clinician awareness), experience, and provider well-being are immediately actualised. These in turn allow for the other aims to occur as a direct outcome of these enhancements.

Policies based on these principles are essential for designing effective economic supports. Through explainable AI systems, value-based care incentives, and appropriate demographic data, outcomes can be improved, and care can be enhanced in any resource setting.

 

Cover image taken from: Chess Health Solutions

Reference url

Recent Posts

EMA CHMP Meeting Highlights
Regulatory Insights from EMA CHMP Meeting Highlights

By HEOR Staff Writer

June 26, 2026

The EMA CHMP Meeting Highlights from 22-25 June 2026 show the committee advancing six new medicines while maintaining rigorous evidentiary standards for complex and rare conditions. Positive opinions covered an inactivated influenza vaccine for adults 50 and older, a levodopa-carbidopa intestinal...
cemdisiran gMG treatment
Breakthrough in cemdisiran gMG treatment Advances Regulatory Landscape

By João L. Carapinha

June 25, 2026

Cemdisiran gMG treatment has cleared a critical hurdle after the FDA and EMA accepted Regeneron’s regulatory submissions for review in anti-AChR antibody-positive generalized myasthenia gravis (gMG). The investigational siRNA therapy targeting complement protein C5 could become the first subcutan...
Trodelvy ADC approval
Advancements in Breast Cancer Treatment Following Trodelvy ADC Approval

By João L. Carapinha

June 25, 2026

The Trodelvy ADC approval by the European Commission delivers the first antibody-drug conjugate approved for first-line use in adults with unresectable or metastatic triple-negative breast cancer who are ineligible for PD-1 or PD-L1 inhibitors. This